Combination therapy for localized pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of drugs for people with localized pancreatic cancer who have already completed 8 cycles of modified FOLFIRINOX chemotherapy before surgery. The goal is to see if adding these drugs after chemo and radiation helps improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with pancreatic ductal adenocarcinoma (a type of pancreatic cancer).
- You must have completed 8 cycles of a chemotherapy called modified FOLFIRINOX before surgery.
- Your cancer must be considered removable by surgery, and you must be eligible for a type of radiation called SBRT.
- You must be 18 years or older and have a good performance status (able to do daily activities without significant help).
- You cannot have received prior immunotherapy drugs or other cancer treatments (except modified FOLFIRINOX).
- You cannot have active autoimmune disease, active infections like HIV or hepatitis, or certain other medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of endoscopic ultrasound-guided heat ablation (RFA) and the immunotherapy drug pembrolizumab for people with locally advanced or metastatic pancreatic cancer that cannot be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.
This Phase 2 trial tests giving chemotherapy plus pembrolizumab (an immunotherapy) before surgery, to shrink or control potentially removable pancreatic cancer. The goal is to improve outcomes while making sure the cancer can still be safely removed by surgery.
This trial tests combining a type of precision radiation (SBRT) with an immunotherapy drug (zimberelimab) for patients with locally advanced pancreatic cancer that cannot be removed by surgery. It aims to see if this combination helps shrink the tumor or control the cancer better.
This trial tests a combination of immunotherapy (PD-1), chemotherapy, and a special type of radiation called PULSAR for patients with locally advanced pancreatic cancer or cancer that has come back only in the pancreas area. The goal is to see if this approach can shrink tumors or keep them from growing.
This trial tests whether adding bortezomib and an immunotherapy drug to standard chemotherapy can help people with pancreatic cancer that has spread to other organs. It is for patients who have not had treatment or whose cancer has worsened after gemcitabine-based chemotherapy.
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.